Alaunos Therapeutics, Inc. (NASDAQ:TCRT) Shares Shorted: Short Interest Up 60.3% in September

Alaunos Therapeutics, Inc. (NASDAQ:TCRT) saw a large increase in short interest in September. As of September 30th, there was short interest totaling 9,736 shares, an increase of 60.3% from the September 15th total of 6,075 shares. Based on an average daily trading volume, of 4,314,053 shares, the short-interest ratio is currently 0.0 days. Approximately 0.5% of the company’s stock are sold short.

Alaunos Therapeutics Price Performance

Shares of Alaunos Therapeutics stock traded up $0.46 during trading on Friday, hitting $2.63. 20,658,613 shares of the company’s stock traded hands, compared to its average volume of 2,104,308. Alaunos Therapeutics has a 1 year low of $0.72 and a 1 year high of $4.50. The business has a 50-day simple moving average of $1.51 and a 200-day simple moving average of $2.09. The stock has a market capitalization of $6.69 million, a P/E ratio of -1.40 and a beta of -0.87.

Alaunos Therapeutics (NASDAQ:TCRT) last issued its earnings results on Friday, August 14th. The company reported ($0.41) earnings per share for the quarter.

Analysts Set New Price Targets

Separately, Weiss Ratings lowered shares of Alaunos Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, August 17th. One research analyst has rated the stock with a Sell rating. According to data from MarketBeat, the company currently has an average rating of “Sell”.

About Alaunos Therapeutics

Alaunos Therapeutics, Inc is a biotechnology company focused on developing genetically engineered T-cell therapies for the treatment of cancer, particularly solid tumors. Its research centers on T-cell receptor (TCR) therapies, which are designed to equip a patient’s immune cells to recognize and attack tumor-specific targets.

The company’s development programs have included TCR-T candidates directed at cancer-associated antigens such as NY-ESO-1 and LAGE-1a. Alaunos has also worked on a TCR library approach intended to support the development of personalized therapies targeting tumor mutations.